Genitourinary Cancers Symposium | Conferences

Nivolumab/Cabozantinib Combo Shows Lasting OS Benefit for RCC in Final Analysis

February 19, 2022

In a final overall survival analysis of CheckMate 9ER, investigators saw a continued survival benefit with first-line nivolumab plus cabozantinib compared with sunitinib in the intention-to-treat patients with untreated clear cell metastatic or advanced renal cell carcinoma.